Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Douglas Dieterich
Icahn School of Medicine at Mount Sinai, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bristol-Meyers Squibb
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Douglas Dieterich serves as a paid lecturer, consultant and for his service on scientific advisory boards of companies which either develop or assess medicines used for the treatment of viral hepatitis.
Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection
End-stage liver disease, predominantly due to hepatitis C virus (HCV) infection, is one of the leading causes of death in person living with HIV infection. While HCV is curable and recent advances in treatment have increased the rates of cure, few patients with HIV and HCV are being treated to cure HCV. This study will develop and test a behavioral intervention to increase the rates of HCV treatment initiation and adherence in HIV-positive persons with HCV co-infection.
Filed on January 15, 2014.
Tell us what you know about Douglas Dieterich's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Douglas Dieterich”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Douglas Dieterich | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Genentech Inc. | $0 - $4,999 |
| Douglas Dieterich | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Merck & Co., Inc. | $20,000 - $39,999 |
| Douglas Dieterich | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Gilead Sciences, Inc. | $40,000 - $59,999 |
| Douglas Dieterich | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Idenix Pharmaceuticals | $0 - $4,999 |
| Douglas Dieterich | Icahn School of Medicine at Mount Sinai | Conflict of Interest | AbbVie | $0 - $4,999 |
| Douglas Dieterich | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Boehringer Ingelheim Corp | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.